MRVI - Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc. , a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
As of May 15, 2026: spot at $4.12, ATM IV 81.6%, net GEX $24.4K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $1.21B
- Beta
- 0.62
- 52-Week Range
- 1.95-4.995
- CEO
- Bernd Brust
- Employees
- 570
- IPO Date
- Nov 20, 2020
- Exchange
- NASDAQ
What MRVI Looks Like to Options Traders Today
IV rank of 13.8% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($24.4K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes.
What This Page Covers
The MRVI overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked MRVI overview questions
- What is MRVI?
- MRVI is the ticker symbol for Maravai LifeSciences Holdings, Inc., a listed security. Maravai LifeSciences Holdings, Inc. , a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. Listed on NASDAQ. MRVI is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the MRVI options snapshot look like today?
- As of May 15, 2026, the MRVI options snapshot shows spot at $4.12, ATM IV 81.6%, IV rank 13.8%, net GEX $24.4K, expected move 23.39%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are MRVI's key statistics?
- Maravai LifeSciences Holdings, Inc. (MRVI) carries a market capitalization of $1.21B, beta of 0.62 relative to the broader market, 52-week range of 1.95-4.995. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does MRVI belong to?
- Maravai LifeSciences Holdings, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare MRVI's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the MRVI data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).